Eurofins Discovery Collaborating with Invasight on Cancer Therapies

15 February 2023 | Wednesday | News

Eurofins Discovery, the leading provider of products and services to the drug discovery industry, today announced its collaboration with Invasight, a Switzerland-based biotech developing cancer therapies. The collaboration focuses on advancing first-in-class, small molecule, protein-protein interaction antagonists (PPIAs) against a protein that causes cancer cell invasion.
Image Source : Public Domain

Image Source : Public Domain

Invasight is teaming with Eurofins Discovery's DiscoveryOne™, an integrated drug discovery platform that provides expert comprehensive support to progress programs from concept to preclinical development and beyond.

Invasight will combine its own breakthrough technology, ACINDA (Anti-cancer Cell Invasion Drug Discovery Accelerator), which closely mimics the in vivo tumor microenvironment, with Eurofins Discovery's fully integrated capabilities that include medicinal chemistry, in vitro pharmacology, ADME-PK, biomarkers and industry-leading safety pharmacology, to progress to a development candidate.

The DiscoveryOne team's successful track record and experience moving candidates effectively from hit to preclinical candidate, coupled with Invasight's proprietary cancer cell invasion models, are expected to result in high-quality molecules moving rapidly to IND-enabling studies to accelerate therapeutics in the fight against cancer.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in